Animal studies have shown no teratogenic or foetotoxic effects of nadroparin, however, currently there are only limited data concerning nadroparina smiling penetration through the placenta in humans. Therefore, the use Fraksiparina during pregnancy is not recommended unless the potential benefit to the arimidex dosage mother outweighs risk to the fetus. Lactation There are currently limited data on the allocation of nadroparin in breast milk. In this regard, the use of nadroparin during breastfeeding is not recommended.
Dosage and administration subcutaneous injection technique is preferably administered with the patient lying in the subcutaneous tissue of the anterolateral or posterolateral surface of the abdomen, alternating left and right sides. Allowed the introduction of the thigh. To prevent loss of drug when using the syringe, you should not remove air bubbles before injection. The needle should be inserted perpendicular and not at an angle oral tren, in the jammed a fold of skin, which must be held between the thumb and index finger to the end of the introduction of the solution. Do not rub the injection site after injection.
Prevention of thromboembolic General Surgery recommended dose arimidex dosage is 0.3 mL (2,850 anti-Xa ME) subcutaneously for 2-4 hours prior to surgery, thenadministered 1 time per day.Treatment is continued for at least 7 days and during the period of risk of thrombus formation, to a patient transfer to outpatient treatment. Orthopedic surgery administered subcutaneously, the dosage depends on the patient’s body weight, and is listed in the table below, the rate weight which can be increased to 50% on the fourth postoperative day. The initial dose is assigned to 12 hours before the operation, the second dose – 12 hours after the end of the operation. Continue to apply 1 time per day during the period of risk of thrombosis to transfer the patient to outpatient treatment. The minimum treatment period is 10 days.
Elderly patients Elderly patients do not require dose adjustments, except patsientoz with impaired renal function. Prior to treatment Fraksiparinom recommended to assess kidney function.
Renal impairment Prevention of thromboembolism: In patients with mild to moderate renal insufficiency (creatinine clearance> 30 ml / min and less than 60 ml / min) dose reduction is not necessary if Fraksiparin used for the prevention of thrombosis. In patients with arimidex dosage severe renal impairment (creatinine clearance less than 30 mL / min), the dose should be reduced by 25%. In patients with severe renal impairment (creatinine clearance less than 30 ml / min), the dose should be reduced by 25%. Treatment of venous thromboembolism, venous thromboembolism prophylaxis in patients metribolone with a high risk tromboobrazvaniya (unstable angina and myocardial infarction without tooth Q): In patients with mild to moderate renal failure Fraksiparin to treat these diseases, the dose should be reduced by 25%.Fraksiparin is contraindicated in patients with severe renal insufficiency.
Patients with hepatic impairment No special investigations carried out for this group of patients.
Adverse reactions Ispolzozana adverse reactions following classification based on the frequency zstrechaemosti: very often (> 1.10), frequent (> 1/100 <1.10), and sometimes (> 1/1000 <1/100), rare ( > 1 / 10,000, <1/1000), very rare (<1 / 10,000). from the circulatory and lymphatic system: very often – hemorrhage of different locations, often in patients with other risk factors for patients; rarely – thrombocytopenia; very rarely – eosinophilia, reversible after discontinuation of therapy. Immune system: very rarely – hypersensitivity reactions (including angioedema and cutaneous reactions). On the part of metabolism: rarely – reversible hyperkalemia related to heparin ability to inhibit the secretion of aldosterone, especially in patients bodybuilding video with risk group. Hepatobiliary disorders: often – increased liver transaminases, bearing usually transient. skin and subcutaneous tissue disorders: very often – the formation of small subcutaneous hematoma at the injection site. In some cases the appearance of dense knots, does not mean encapsulation of heparin, which disappear in a few days. Very rarely – necrosis of the skin, usually at the injection site. Necrosis is usually preceded by purpura or infiltrated or painful erythematous patch, which can be accompanied or not accompanied by common symptoms. In such cases, treatment should be discontinued immediately Fraksiparinom. On the part arimidex dosage of the reproductive system: very rarely – priapism.